(Q37709191)

22 August 2017

1 reference

title

Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus (English)

1 reference

22 August 2017

0 references

coronary artery disease

1 reference

Johann Wojta

4

0 references

Alexandra Kautzky-Willer

object named as

Alexandra Kautzky-Willer

3

0 references

author name string

Serdar Farhan

1

1 reference

22 August 2017

Thomas Höchtl

2

1 reference

22 August 2017

Kurt Huber

5

1 reference

22 August 2017

publication date

1 January 2010

1 reference

Wiener Medizinische Wochenschrift

22 August 2017

published in

1 reference

22 August 2017

volume

160

1 reference

22 August 2017

issue

1-2

1 reference

22 August 2017

page(s)

30-38

1 reference

Aspirin therapy in diabetes

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10354-010-0747-8

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10354-010-0747-8

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10354-010-0747-8

Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.

21 January 2018

1 reference

12 December 2020

Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents

1 reference

12 December 2020

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

12 December 2020

Insulin resistance and human disease: a short history

1 reference

12 December 2020

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial

1 reference

12 December 2020

High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial

1 reference

12 December 2020

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

1 reference

12 December 2020

Hyperglycemia Stimulates Coagulation, Whereas Hyperinsulinemia Impairs Fibrinolysis in Healthy Humans

1 reference

12 December 2020

Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview

1 reference

12 December 2020

Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial

1 reference

12 December 2020

Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration

1 reference

12 December 2020

Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states

1 reference

12 December 2020

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

12 December 2020

Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome

1 reference

12 December 2020

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

1 reference

12 December 2020

Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention

1 reference

12 December 2020

Increased Platelet Aggregation in Early Diabetus Mellitus

1 reference

12 December 2020

Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo

1 reference

12 December 2020

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

12 December 2020

Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria.

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)

1 reference

12 December 2020

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatmen

1 reference

12 December 2020

Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes

1 reference

12 December 2020

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

12 December 2020

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial

1 reference

12 December 2020

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

1 reference

12 December 2020

Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease

1 reference

12 December 2020

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

1 reference

12 December 2020

Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction

1 reference

12 December 2020

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial

1 reference

12 December 2020

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention

1 reference

12 December 2020

Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and

1 reference

12 December 2020

Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin

1 reference

12 December 2020

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

12 December 2020

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

1 reference

12 December 2020

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

1 reference

12 December 2020

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment

1 reference

12 December 2020

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

12 December 2020

Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients

1 reference

12 December 2020

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

1 reference

12 December 2020

Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial

1 reference

12 December 2020

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

1 reference

12 December 2020

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

12 December 2020

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

1 reference

12 December 2020

Review of prasugrel for the secondary prevention of atherothrombosis

1 reference

12 December 2020

Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

1 reference

12 December 2020

Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomi

1 reference

12 December 2020

Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects

1 reference

12 December 2020

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

1 reference

12 December 2020

Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study.

1 reference

12 December 2020

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

12 December 2020

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction

1 reference

12 December 2020

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

1 reference

12 December 2020

Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials

1 reference

12 December 2020

New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes

1 reference

12 December 2020

The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial

1 reference

12 December 2020

Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus

1 reference

12 December 2020

Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.

1 reference

12 December 2020

Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (

1 reference

12 December 2020

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

1 reference

12 December 2020

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

1 reference

12 December 2020

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

1 reference

12 December 2020

Thrombin-antithrombin III complexes in type II diabetes mellitus

1 reference

12 December 2020

A survey of drug treatment and outcomes in diabetic patients with acute myocardial infarcts.

1 reference

12 December 2020

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

1 reference

12 December 2020

The platelet in diabetes: focus on prevention of ischemic events

1 reference

12 December 2020

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

12 December 2020

Platelet dysfunction in type 2 diabetes

1 reference

12 December 2020

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel

1 reference

12 December 2020

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

1 reference

12 December 2020

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

12 December 2020

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

1 reference

12 December 2020

Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes

1 reference

12 December 2020

Change of lipoprotein (a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy

1 reference

12 December 2020

Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors

1 reference

12 December 2020

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

1 reference

12 December 2020

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Interventio

1 reference

12 December 2020

10.1007/S10354-010-0747-8

Identifiers

DOI

1 reference

22 August 2017

1 reference